The Combined Role of Immunotherapy and Radiotherapy in Muscle-Invasive Bladder Cancer: A Systematic Review
DOI:
https://doi.org/10.55606/jurrikes.v5i2.9333Keywords:
Bladder Cancer, Immunotherapy, PD-L1, Radiotherapy, Systematic ReviewAbstract
Muscle-invasive bladder cancer (MIBC) is an aggressive malignancy associated with high morbidity, reduced survival, and impaired quality of life. Radiotherapy (RT) has been widely used as a bladder-preserving strategy, particularly for patients unsuitable for surgery or systemic chemotherapy. RT may also enhance tumor immunogenicity through programmed death-ligand 1 (PD-L1) upregulation, providing a rationale for combination therapy with immunotherapy. This study aimed to evaluate the effectiveness of combining immunotherapy and radiotherapy in MIBC treatment. A systematic review was conducted following PRISMA 2020 guidelines using the PICO framework. Literature searches were performed in PubMed, Embase, Cochrane, ClinicalTrials.gov, Web of Science, and Scopus databases for studies published between 2016 and 2025. Risk of bias was assessed using the Cochrane Risk of Bias Tool and ROBINS-I. Of 105 identified studies, five met the inclusion criteria and were included in the final analysis. Only one Phase II randomized controlled trial demonstrated low risk of bias in randomization and allocation concealment. ROBINS-I assessment indicated moderate to serious risk in confounding and participant selection domains. Clinical findings showed promising outcomes, with complete response rates ranging from 35%–50% and partial response rates from 25%–40%. Median overall survival ranged from 24–30 months, with favorable disease-free and progression-free survival outcomes. Combined immunotherapy and radiotherapy demonstrate potential to improve survival and disease control in MIBC; however, further rigorous clinical studies are needed to optimize patient-centered treatment strategies.
Downloads
References
Bray, F., Laversanne, M., & Sung, H. (2024). Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 74(3), 229–263. https://doi.org/10.3322/caac.21834
Daro-Faye, M., Kassouf, W., & Souhami, L. (2021). Combined Radiotherapy and Immunotherapy in Urothelial Bladder Cancer: Harnessing the Full Potential of the Anti-Tumor Immune Response. World J Urol, 39, 1331–1343. https://doi.org/10.1007/s00345-020-03440-4
Demars, M. M., & Perruso, C. (2022). Mesh and Text-Word Search Strategies: Precision, Recall, and Their Implications for Library Instruction. J Medical Library Association, 110(1), 23–33. https://doi.org/10.5195/jmla.2022.1283
Guerrero-Ramos, F., González-Padilla, D. A., Pérez-Cadavid, S., García-Rojo, E., Tejido-Sánchez, Á., Hernández-Arroyo, M., Gómez-Cañizo, C., & Rodríguez-Antolín, A. (2024). Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs. Cancers, 16(19), 3330. https://doi.org/10.3390/cancers16193330
Haddaway, N. R., Page, M. J., Pritchard, C. C., & McGuinness, L. A. (2022). PRISMA2020: An R Package and Shiny app for Producing PRISMA 2020-Compliant Flow Diagrams, with Interactivity for Optimised Digital Transparency and Open Synthesis. Campbell Systematic Reviews, 18,1230. https://doi.org/10.1002/cl2.1230
Higgins, J. P. T., Savović, J., Page, M. J., Elbers, R. G., Sterne, J. A. C., Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., & Page, M. J. (2019). Chapter 8: Assessing Risk of Bias in a Randomized Trial. Cochrane Handbook for Systematic Reviews of Interventions, 205–228. https://doi.org/10.1002/9781119536604.ch8
Kassouf, W., S., C., I., D., M., B., M., R., & A., D. (2022). CCTG BL13: a Randomized Phase II Trial Assessing Trimodality Therapy with or without Adjuvant Durvalumab to Treat Patients with Muscle-Invasive Bladder Cancer (NCT03768570. Journal of Clinical Oncology, 40(16). https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS4619
Ran, Z., & Chang-Xing, K. (2025). Advances in Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer. Front. Oncol, 15,1562260. https://doi.org/10.3389/fonc.2025.1562260
Rizzo, M., Soares, A., & Grande, E. (2024). Radiotherapy Plus Pembrolizumab for Advanced Urothelial Carcinoma: Results from the ARON-2 Real-World Study. Sci Rep, 14,19802. https://doi.org/10.1038/s41598-024-70182-3
Ruiter, B. M., J.W., H., D., L., T.M., R., R.J.A., M., & E.J., G. (2022). Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer. European Urology, 82(5), 518–526. https://doi.org/10.1016/j.eururo.2022.07.009
Schmid, S. C., K., S., J., L., A.K., S., A., S., & F, K. (2022). et al.LBA75 RACE IT: A Prospective, Single Arm, Multicenter, Phase II-Trial to Assess Safety and Efficacy of Preoperative RAdiation Therapy Before Radical CystEctomy Combined with ImmunoTherapy in Locally Advanced Urothelial Carcinoma of the Bladder (AB 6. Annals of Oncology, 33, 1442. https://doi.org/10.1016/j.annonc.2022.08.081
Schmid, S. C., Koll, F. J., & Rödel, C. (2020). Radiation Therapy Before Radical Cystectomy Combined with Immunotherapy in Locally Advanced Bladder Cancer – Study Protocol of a Prospective, Single Arm, Multicenter Phase II Trial (RACE IT. BMC Cancer, 20(8), 1–9. https://doi.org/10.1186/s12885-019-6503-6
Sterne, J. A. C., Hernán, M. A., McAleenan, A., Reeves, B. C., Higgins, J. P. T., Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., & Page, M. J. (2019). Chapter 25: Assessing Risk of Bias in a Non-Randomized Study. Cochrane Handbook for Systematic Reviews of Interventions, 621–642. https://doi.org/10.1002/9781119536604.ch25
Wen, F., T., L., P., Z., P., T., X., Z., & Y, S. (2023). A Phase 2, Open-label Study of Neoadjuvant Chemotherapy Plus Tislelizumab Followed by Radiotherapy-based, Bladder-Preserving Treatment for High Risk/Locally Advanced Muscle Invasive Urothelial Bladder Cancer (HOPE-02. Journal of Clinical Oncology, 41(6), 516–516. https://doi.org/10.1200/JCO.2023.41.6_suppl.516
Wu, C. T., Chen, W. C., Chang, Y. H., Lin, W. Y., & Chen, M. F. (2016). The Role of PD-L1 in the Radiation Response and Clinical Outcome for Bladder Cancer. Sci Rep, 6,19740. https://doi.org/10.1038/srep19740
Wu, M., Huang, Q., & Xie, Y. (2022). Improvement of the Anticancer Efficacy of PD-1/PD-L1 Blockade via Combination Therapy and PD-L1 Regulation. J Hematol Oncol, 15(24), 1–58. https://doi.org/10.1186/s13045-022-01242-2
Yongsoo, J., & Dong, Y. H. (2024). Trimodal Therapy in the Treatment of Muscle-Invasive Bladder Cancer. J Urol Oncol, 22(3), 256–267. https://doi.org/10.22465/juo.244801000050
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Aristya Ika Wardani
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
_001.jpg)
